SQZ Biotechnologies Co. (SQZ) News

SQZ Biotechnologies Co. (SQZ): $7.33

-0.30 (-3.93%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SQZ to Watchlist
Sign Up

Industry: Biotech


Ranked

of 453

in industry

Filter SQZ News Items

SQZ News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SQZ News Highlights

  • For SQZ, its 30 day story count is now at 2.
  • Over the past 21 days, the trend for SQZ's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about SQZ are IO.

Latest SQZ News From Around the Web

Below are the latest news stories about SQZ Biotechnologies Co that investors may wish to consider to help them evaluate SQZ as an investment opportunity.

SQZ Biotechnologies Announces Healthcare Industry Leader John Maraganore, Ph.D. Joining as Strategic Advisor

WATERTOWN, Mass., January 06, 2022--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that John Maraganore, Ph.D., founding CEO of Alnylam Pharmaceuticals, has joined the company as a strategic advisor.

Yahoo | January 6, 2022

SQZ: Preliminary Results Feature Patient 17

By John Vandermosten, CFA NYSE:SQZ READ THE FULL SQZ RESEARCH REPORT ESMO-IO Preliminary Results and Webcast/Conference Call SQZ Biotechnologies Company (NYSE:SQZ) hosted a webcast and conference call on December 9, 2021 to discuss updates to SQZ-PBMC-HPV-101 program at ESMO 1 Immuno-Oncology Congress 2021. SQZ-PBMC-HPV-101 is the company’s antigen presenting cell (APC) lead program. Jong Chul

Yahoo | December 16, 2021

SQZ Biotechnologies Announces Lead Cell Therapy Candidate Induced Radiographic, Symptomatic and Immune Response as Monotherapy in Post-Checkpoint HPV+ Solid Tumor Patient

WATERTOWN, Mass., December 09, 2021--SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today presented interim results from the highest-dose cohort of its ongoing Phase 1/2 clinical trial of lead Antigen Presenting Cell (APC) therapy candidate targeting Human Papillomavirus positive (HPV16+) solid tumors at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress. Of the five patients in this cohort eva

Yahoo | December 9, 2021

SQZ Biotechnologies Lead Cell Therapy Candidate Generated Monotherapy Clinical Response Correlated with Substantial CD8 T Cell Tumor Infiltration in HPV+ Solid Tumor at Highest Dose

WATERTOWN, Mass., December 02, 2021--SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced interim results from the highest-dose monotherapy cohort of its ongoing Phase 1/2 clinical trial of SQZ-PBMC-HPV, an investigational cell therapy being evaluated in certain patients with advanced or metastatic Human Papillomavirus positive (HPV16+) solid tumors. In an abstract published today by the European Society for M

Yahoo | December 2, 2021

SQZ Biotechnologies Announces Acceptance by Roche Accelerator in China

WATERTOWN, Mass., December 01, 2021--SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that its China Initiative has been accepted by the Roche Accelerator. Launched earlier this year, the accelerator is Roche’s first in-house accelerator globally and further establishes its long-term commitment to Shanghai and China. China’s healthcare ecosystem is of growing global importance and provides significant oppo

Yahoo | December 1, 2021

SQZ: Something New to Squeeze Into Your Portfolio

By John Vandermosten, CFA NYSE:SQZ READ THE FULL SQZ RESEARCH REPORT We are initiating coverage of SQZ Biotechnologies Company (NYSE:SQZ) with a current valuation of $30.00 per share. This present value is based on our estimates for a successful development of the Antigen Presenting Cell (APC), Activating Antigen Carrier (AAC) and Tolerizing Antigen Carrier (TAC) platforms in HPV positive solid

Yahoo | November 30, 2021

SQZ Biotechnologies to Present at the 4th Annual Evercore ISI HealthCONx Conference

WATERTOWN, Mass., November 29, 2021--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be presenting at the 4th Annual Evercore ISI HealthCONx Conference on December 1st. Armon Sharei, Ph.D., Chief Executive Officer, will present a corporate overview and the company will be hosting one-on-one meetings.

Yahoo | November 29, 2021

SQZ Biotechnologies to Present at the Stifel 2021 Virtual Healthcare Conference

WATERTOWN, Mass., November 15, 2021--SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be presenting at the Stifel 2021 Virtual Healthcare Conference on November 17. Armon Sharei, Ph.D., Chief Executive Officer, will present a corporate overview and the company will be hosting one-on-one meetings.

Yahoo | November 15, 2021

SQZ Biotechnologies Presents New AAC, eAPC Platform Research and First Enhanced Tumor Infiltrating Lymphocyte Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting

WATERTOWN, Mass., November 12, 2021--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today presented new SQZ™ AAC and eAPC preclinical research describing the robust potential of these platforms to treat cancer, including data demonstrating synergistic activity when combined with chemotherapy. The company also presented new research on the development of enhanced tumor infiltrating lymphocytes (TILs) that show increased p

Yahoo | November 12, 2021

SQZ Biotechnologies Reports Third Quarter 2021 Financial Results and Recent Portfolio Updates

WATERTOWN, Mass., November 10, 2021--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today reported third quarter 2021 financial results and recent portfolio updates.

Yahoo | November 10, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.483 seconds.